| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Bortezomib | FIMM | pan-cancer | AAC | -0.43 | 0.002 |
| mRNA | Doxorubicin | gCSI | pan-cancer | AAC | -0.16 | 0.002 |
| mRNA | chlorambucil | CTRPv2 | pan-cancer | AAC | 0.092 | 0.002 |
| mRNA | BRD-K01737880 | CTRPv2 | pan-cancer | AAC | 0.32 | 0.003 |
| mRNA | dabrafenib | GDSC1000 | pan-cancer | AAC | -0.088 | 0.004 |
| mRNA | VX-680 | CTRPv2 | pan-cancer | AAC | 0.28 | 0.004 |
| mRNA | BRD-K27188169:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.14 | 0.004 |
| mRNA | PRIMA-1-Met | CTRPv2 | pan-cancer | AAC | 0.15 | 0.004 |
| mRNA | SKI-II | CTRPv2 | pan-cancer | AAC | 0.1 | 0.004 |
| mRNA | RDEA119 | GDSC1000 | pan-cancer | AAC | -0.086 | 0.005 |